UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extreme Events in Finance: A Handbook of Extreme Value Theory and Its Applications

Longin, Francois

1, 2016

Volltextzugriff (PDF)

Posture analysis in predicting fall-related injuries during French Navy Special Forces selection course using machine learning: a proof-of-concept study

BMJ military health, 2023-12, p.e002542

2023

Volltextzugriff (PDF)

A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

Annals of oncology, 2016-10, Vol.27, p.vi98-vi98

2016

Volltextzugriff (PDF)

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii709-viii709

2018

Volltextzugriff (PDF)

Comparison of anti-fading agents used in fluorescence microscopy: image analysis and laser confocal microscopy study

The Journal of histochemistry and cytochemistry, 1993-12, Vol.41 (12), p.1833-1840

1993

Volltextzugriff (PDF)

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS3-08-GS3-08

2019

Volltextzugriff (PDF)

LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-04-OT2-01-04

2017

Volltextzugriff (PDF)

137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

Annals of oncology, 2016-12, Vol.27, p.ix41-ix41

2016

Volltextzugriff (PDF)

Bootstrap Methods in Statistics of Extremes

Extreme Events in Finance, 2016, p.117-138

2016

Volltextzugriff (PDF)

Estimation Methods for Value at Risk

Extreme Events in Finance, 2016, p.283-356

2016

Volltextzugriff (PDF)

Presence of Zinc and Calcium Permeant Channels in the Inner Membrane of the Nuclear Envelope

Biochemical and biophysical research communications, 1997-06, Vol.235 (1), p.236-241

1997

Volltextzugriff (PDF)

Extreme Value Theory: An Introductory Overview

Extreme Events in Finance, 2016, p.53-95

2016

Volltextzugriff (PDF)

Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316)

Journal of thrombosis and haemostasis, 2011-10, Vol.9 (10), p.2100-2102

2011

Volltextzugriff (PDF)

Statistics of Extremes: Challenges and Opportunities

Extreme Events in Finance, 2016

Longin, Francois

2016

Volltextzugriff (PDF)

The Extreme Value Problem in Finance: Comparing the Pragmatic Program with the Mandelbrot Program

Extreme Events in Finance, 2016 (1), p.25-51

2016

Volltextzugriff (PDF)

Estimation of the Extreme Value Index

Extreme Events in Finance, 2016, p.97-115

2016

Volltextzugriff (PDF)

Extreme Values Statistics for Markov Chains with Applications to Finance and Insurance

Extreme Events in Finance, 2016, p.139-170

2016

Volltextzugriff (PDF)

Lévy Processes and Extreme Value Theory

Extreme Events in Finance, 2016 (1), p.171-193

2016

Volltextzugriff (PDF)

Extreme Value Theory and Risk Management in Electricity Markets

Extreme Events in Finance, 2016, p.405-425

2016

Volltextzugriff (PDF)

The Robotization of Financial Activities: A Cybernetic Perspective

Extreme Events in Finance, 2016, p.529-543

2016

Volltextzugriff (PDF)

The Sortino Ratio and Extreme Value Theory: An Application to Asset Allocation

Extreme Events in Finance, 2016, p.443-464

2016

Volltextzugriff (PDF)

Margin Setting and Extreme Value Theory

Extreme Events in Finance, 2016, p.427-441

2016

Volltextzugriff (PDF)

1 – 25 von 1.135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(817)
Mit Volltextzugriff
(925)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(605)
Life Sciences & Biomedicine
(318)
Technology
(227)
Computer Science
(199)
Humans
(189)
Computer Science, Artificial Intelligence
(140)
Female
(113)
Physical Sciences
(101)
Engineering
(96)
Life Sciences
(87)
Male
(86)
Agriculture
(79)
Engineering, Electrical & Electronic
(76)
Plant Sciences
(76)
Biological And Medical Sciences
(74)
Artificial Intelligence
(71)
Exact Sciences And Technology
(70)
Wheat
(70)
Agronomy
(67)
Chemistry
(64)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Extreme Events in Finance: A Handbook of Extreme Value Theory and Its Applications

Posture analysis in predicting fall-related injuries during French Navy Special Forces selection course using machine learning: a proof-of-concept study

A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Comparison of anti-fading agents used in fluorescence microscopy: image analysis and laser confocal microscopy study

“Artificial intelligence”: Which services, which applications, which results and which development today in clinical research? Which impact on the quality of care? Which recommendations?

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

Bootstrap Methods in Statistics of Extremes

Estimation Methods for Value at Risk

Presence of Zinc and Calcium Permeant Channels in the Inner Membrane of the Nuclear Envelope

Extreme Value Theory: An Introductory Overview

Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316)

Statistics of Extremes: Challenges and Opportunities

The Extreme Value Problem in Finance: Comparing the Pragmatic Program with the Mandelbrot Program

Estimation of the Extreme Value Index

Extreme Values Statistics for Markov Chains with Applications to Finance and Insurance

Lévy Processes and Extreme Value Theory

Extreme Value Theory and Risk Management in Electricity Markets

The Robotization of Financial Activities: A Cybernetic Perspective

The Sortino Ratio and Extreme Value Theory: An Application to Asset Allocation

Margin Setting and Extreme Value Theory

Suchergebnisse filtern